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Abstract
In spite of decades of epidemiological research, the etiology and causal patterns for many common
diseases, such as breast and colon cancer or neurodegenerative diseases, are still largely unknown.
Such chronic diseases are likely to have an environmental origin. However, "environmental" risks
have been often elusive in epidemiological studies. This is a conundrum for current epidemiological
research. On the other side, the relative contribution of genes to chronic diseases, as emerging
from GWAS, seems to be modest (15-50% increase in disease risk). What is yet to be explored
extensively is a model of disease based on long-term effects of low doses of environmental
exposures, incorporating both genetic and acquired susceptibility ("clinical vulnerability"), and the
cumulative effects of different exposures. Such a disease model would be compatible with the weak
associations found by GWAS and the still elusive role of many (low-level) environmental
exposures. We also propose that the introduction of "-omic" high-throughput technologies, such
as transcriptomics, proteomics and metabolomics, may provide, in the next years, powerful tools
to investigate early effects of environmental exposures and understand the etiology of common
diseases better, according to the "clinical vulnerability model". The development of "-omics", in
spite of current limitations and lack of sound validation, could greatly contribute to the elucidation
of the disease model we propose.
Introduction
We are still far from completely understanding the etiol-
ogy and causal patterns for many common diseases, such
as breast and colon cancer, or neurodegenerative diseases.
In spite of decades of epidemiological research, the etiol-
ogy of many such conditions is still largely unknown.
For a long time it has been hypothesized that most
chronic diseases have an environmental origin (using the
term "environment" in a broad sense, to indicate essen-
tially what is not due to genetic predisposition). This
claim was based on descriptive data showing the broad
range of incidence rates in different parts of the world, the
rapid temporal changes - such as those currently occurring
in China and India - and the crucial observation of inci-
dence rates in migrant populations. The latter unequivo-
cally showed that migrants rapidly acquire - sometimes
already in the first generation after migration - the risk of
disease that is typical of the population where they move.
However, "environmental" risks have been largely elusive
in epidemiological research, and there is still much debate
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on the real impact of the environment, whose role tends
to be overshadowed in recent times by the successes of
genetics, in particular Genome-wide association studies
(GWAS). Clearly, we need a disease model that allows us
to encompass both the mass of genetic data coming from
GWAS and the still elusive role of many environmental
exposures.
Genes vs. environment
The technological revolution in genetics, which in 2007-
2009 led to the identification of a number of novel genes
for several common diseases, is inspiring but at the same
time a little disappointing. Most highly-penetrant genes
had already been uncovered by linkage studies, so that
"genome-wide scans" could mainly identify low-pene-
trant genes. It is a fact that - with a few exceptions - what
has been found is genetic variants weakly associated with
chronic diseases, with relative risks of 1.15-1.5. These risks
are much lower than some known environmental expo-
sures, and of the same order of magnitude of environmen-
tal exposures that are usually rejected as too weakly
associated with disease to be meaningful or interpretable.
For example, Hung et al have found an allelic relative risk
of 1.3 for a gene variant associated with lung cancer, in the
putative nicotinic acetylcholine receptor subunit on chro-
mosome 15q25 [1]. The genotype nicely combines with
the habit of smoking, increasing the probability of devel-
oping lung cancer in smokers (Figure 1) [1]. However, it
is clear from the figure that the effect of smoking is by far
greater than the effect of the genotype. The former
increases the cumulative risk in life from less than 1%
(non smokers who have never smoked) to about 15-20%
(current smokers), while the effect of the genotype is a
small additional amount (~1 to 2%) that does not seem
to contribute much to the Public Health problem of lung
cancer.
Of course genetic research is not tailored for Public Health
purposes. It can be worthwhile, instead, (a) for the inves-
tigation of disease mechanisms, (b) to shed light on
potential therapies, or (c) to suggest clues for unidentified
etiological agents in the case of diseases whose etiology is
still unknown. It is unclear, however, how goals (b) and
(c) can be met if the relative contribution of genes is so
small (15-50% increase in disease risk) being in the same
order of magnitude of relative risks found for unclear and
controversial environmental exposures, such as electro-
magnetic fields and leukemia, or some pesticides and
prostate cancer. It is therefore useful to reflect on the
potential reasons why weak genetic associations (gener-
ally) are perceived as much more noteworthy than envi-
ronmental associations.
1. One reason - perhaps the main one - is certainly the
greater robustness of technical detection of gene variants
compared to environmental exposures. It is estimated that
the error rate with common genotyping techniques is less
than 10%, while it can be as high as 50% for environmen-
tal exposure assessment, at least for dichotomous expo-
sure variables. Moreover genes are stable in the course of
life, while environmental exposures are changing over
time (let us think of diet) leading to more inherent meas-
urement error in environmental exposure than in gene
variance assessment.
2. A second obvious reason is replication. In the study
mentioned above on lung cancer, the association was
found in five independent studies. This usually is not the
case for environmental exposures, where replication is not
easily achievable. For example, a cohort study from Bel-
gium suggested that high levels of cadmium in urine are
associated rather strongly with lung cancer [2]. The study
is strong (though small), because exposure assessment is
based on a biomarker reflecting long-term exposure (i.e.
with much higher accuracy than usually available in epi-
demiology). However, the study is not easily reproduci-
ble, because there are not many other populations with
similar levels of environmental exposure to cadmium,
Cumulative risk of lung cancer by rs8034191 genotype Figure 1
Cumulative risk of lung cancer by rs8034191 geno-
type. Relevance of smoking and of rs8034191 genotype to 
lung cancer mortality in men aged 45-75 years. Cumulative 
risk (in the absence of other causes of death) based on 
national lung cancer death rates for men in Poland in the year 
2000, assuming that the prevalence of current smoking, 
former smoking, and never smoking are as in this study and 
that the relative risks for lung cancer incidence and mortality 
are similar (Hung et al 2008) [1].Environmental Health 2009, 8:54 http://www.ehjournal.net/content/8/1/54
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and there might be several confounders or effect modifiers
that either obscure the association with cadmium or
change the strength of the association. This is commonly
observed in environmental epidemiology, i.e. a number
of small-medium size associations that are difficult to
reproduce in different settings, both because of methodo-
logical difficulties and because of variable study contexts.
Low doses and acquired susceptibility to disease
In spite of the limitations of environmental epidemiol-
ogy, in particular of exposure assessment, we have seen
recently increasing ability of epidemiological tools to con-
sistently unravel the effects of low-level environmental
exposures. The cases of air pollution and environmental
tobacco smoke (also called ETS, secondhand smoke or
passive smoke) are exemplar. In the seventies and eighties
many researchers thought it was impossible to detect
plausible causal associations with such low-level expo-
sures. The underlying idea was that "noise" (bias, con-
founding) was larger than the signal. However, a large
number of well-conducted studies have been published
since: in the case of ETS more than 60 studies show (with
few exceptions) increased risks of lung cancer in the order
of 1.25, i.e. the same magnitude as the gene for the nico-
tine acetylcholine receptor [3]. For air pollution, an asso-
ciation with lung cancer has been reported in six cohort
studies. One of these studies is sufficiently large as to
show the association in non-smokers [3,4]. Again, the rel-
ative risk is around 1.25. In both cases biomarkers, such
as cotinine or NNK for ETS and DNA adducts for air pol-
lution, have contributed to make the association more
plausibly causal.
We have thus to acknowledge that ETS and air pollution
(mainly due to traffic exhaust) are able to induce, after
long-term exposure, chronic diseases such as cancer and
also coronary artery disease. The interesting observation is
that this happens at dose levels that are much lower than
those of tobacco smoke or "classical" carcinogens. For
example, exposure to ETS occurs at levels that are 1/100
compared to active smoking [5].
One potential explanation for the effects of low doses and
the absence of a threshold is based on acquired suscepti-
bility and the cumulative effects of different exposures. As
defined by Rothman and Greenland, "the cause of a dis-
ease event is an antecedent event, condition or character-
istic that was necessary (given that all other conditions are
fixed) for the occurrence of the disease at the moment it
occurred" [6]. Said in other words, a cause can also be
viewed as something that "completes an incomplete
causal chain" [7] or precipitates a chain of events, which
creates a state of vulnerability. This concept of "clinical
vulnerability" is expressed in Figure 2[8]. Exposure to low
levels of e.g. ETS or air pollution is not a "cause" of cancer
in itself (like an accident is the cause of a death), but
because it occurs on top of pre-existing vulnerability. This
could well explain why small changes in environmental
exposures can have big effects, if they occur in a popula-
tion of vulnerable subjects.
Vulnerability can be acquired or genetically-based. The
concept of acquired "clinical vulnerability" is related to
previous insults/pathophysiological changes that predis-
pose to disease, as expressed in Figure 2. An example is the
finding of a greater effect of ETS among ex-smokers com-
pared to non smokers who have never smoked in a large
prospective investigation [9]. It is plausible that ex-smok-
ers have a greater vulnerability because of already existing
mutations or epigenetic changes, so that further exposure
to ETS leads to selection and clonal expansion of mutated
cells.
Another type of vulnerability (more often called hyper-
susceptibility) is genetically determined. Many years ago
we showed that subjects with the genetically based NAT2
slow acetylator genotype could have greater susceptibility
to adverse biological and/or health effects by tobacco
smoke related arylamines at lower levels of exposure
rather than at higher levels [10]. Our reasoning was that
on very rare occasions, e.g. among people exposed to high
doses of potent carcinogens, the whole population or a
vast majority develops cancer. This is what happened
among British chemical workers exposed to 2-naphthyl-
amine in the 1950s and before. For example, all 15 work-
ers exposed to 2-naphthylamine in a plant developed
Vulnerability plus exposure events change the physiological  state, but a reserve is present Figure 2
Vulnerability plus exposure events change the physi-
ological state, but a reserve is present. When the 
reserve is overtaken, clinical manifestations appear. From 
http://www.sahsu.org/jubilee_presentations/Ander-
son.ppt#392,21, courtesy of R Anderson.Environmental Health 2009, 8:54 http://www.ehjournal.net/content/8/1/54
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bladder cancer, probably one of the few examples of a
"sufficient" exposure in the history of carcinogenesis [11].
It is clear that in that case genetic susceptibility was totally
irrelevant. In most cases, however, when exposure levels
are lower or much lower, genetic susceptibility can play a
role in modulating individual risk.
The contribution of intermediate biomarkers 
and '-omics'
The concept of acquired "clinical vulnerability" is related
to previous insults/pathophysiological changes that pre-
dispose to disease. Intermediate markers and specifically
'-omics' could be particularly useful in tracing the "his-
tory" of such insults and in reflecting the cumulative effect
of different exposures.
Intermediate Biomarkers
Intermediate biomarkers directly or indirectly represent
events on the continuum between exposure and disease.
Intermediate biomarkers can provide important mecha-
nistic insight into the pathogenesis of environmental dis-
eases. As such, they complement classic epidemiological
studies that use disease endpoints. Examples of early bio-
logic effect biomarkers include measures of cellular toxic-
ity, chromosomal alterations, DNA, RNA and protein
expression, and early non-neoplastic alterations in cell
function (e.g., altered DNA repair, altered immune func-
tion). For maximum utility, an intermediate biomarker
must be shown to be predictive of developing disease. The
criteria for validating intermediate biomarkers have been
discussed by Schatzkin and colleagues [12,13] and focus
on the calculation of the etiologic fraction of the interme-
diate endpoint, which varies from 0 to 1. The closer the
etiologic fraction is to 1, the more the biologic marker
reflects events, either directly or indirectly, on the causal
pathway to disease. For instance, bone-marrow toxicity
has been linked to future risk of leukemia. Therefore, envi-
ronmental exposures that lead to bone-marrow toxicity
are potentially leukemogens. Bone-marrow toxicity can be
measured by studying peripheral blood cell counts
including circulating progenitor cells. Studies based on
such endpoints have the advantage that the biological
marker can be measured quantitatively and therefore
increase the power as compared to dichotomous (rare)
disease endpoints. Furthermore, these studies can be car-
ried out using cross-sectional or semi-longitudinal study
designs in which exposure can be accurately assessed. An
example of the use of intermediate markers is a recent
study on hematological effects of benzene at low levels of
exposure [14]. In this study peripheral blood cells and
progenitor cell colony formation were significantly
decreased among low exposed individuals in a dose-
dependent matter. Moreover, these effects occurred at
exposure levels that were lower than previously thought
safe [14].
-Omics
"-Omics" tools can be directly applied to samples from an
epidemiologic case-control or cohort study to better char-
acterise intermediate pathways, potentially providing the
'missing links' among exposures, genes, and diseases [15].
The term "-omics" generally refers to the rigorous study of
a complete set of biological molecules with high-through-
put techniques [16]. One of the main hallmarks is the
departure from traditional molecular biology focusing on
a single biological structure (e.g. a single gene or protein)
to a more comprehensive analysis of biological systems.
Cells and tissues alter their metabolism or gene expression
in response to exposure as indicated by, for example, the
induction of specific groups of genes in response to heat
shock, hypoxia, or osmotic stress [17-19]. These responses
can produce patterns of specific changes in gene expres-
sion, proteins, or metabolic profiles that reflect exposure
to a particular agent or class of agents which can be inter-
preted as a "history" of such exposures and might reflect
the cumulative effect of different exposures. Some of the
"-omic" technologies in environmental health that offer
new opportunities to detect and quantify these changes
are discussed below (also see table 1). We propose some
examples of uses of "-omics" in environmental health,
mainly to elucidate which kind of contributions we may
expect.
Transcriptomics
Transcriptomics is a mature technology, however still
strongly constrained by the intrinsic heterogeneity and
instability of mRNA. It focuses on gene expression profil-
ing, which can be used to determine which genes are dif-
ferently expressed as a result of changes in environmental
conditions. A study typically involves a group of individ-
uals with similar exposure level or phenotype (e.g. disease
status) and compares the gene expression profile of this
group to the profile of a reference group. To avoid the
problems of large interindividual variations compared
with the small changes caused by environmental expo-
sure, Wang et al conducted a self-controlled study design,
with measurements made before and after individual
exposure to welding fumes. The group was stratified
according to smoking status (which profoundly affected
the expression profiles). Nonsmokers after exposure to
welding fumes exhibited altered gene expression in 35
genes from eight functional pathways, including proc-
esses related to oxidative stress, proinflammatory
responses, phosphate metabolism, cell proliferation, and
apoptosis [20].
A study by Lu et al used a human cancer cDNA expression
array to detect differential gene expression patterns deter-
mined in liver tissue samples from arsenic exposed indi-
viduals and healthy liver tissues [21]. Approximately 60Environmental Health 2009, 8:54 http://www.ehjournal.net/content/8/1/54
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genes (10%) were differentially expressed in arsenic
exposed human liver tissues compared to controls. The
differentially expressed genes included those involved in
cell-cycle regulation, apoptosis, DNA damage response
and intermediate filaments. The observed gene alterations
appeared to be reflective of hepatic degenerative lesions
seen in arsenic-exposed patients.
However, transcriptomic changes are likely to be tempo-
rary, i.e. reflect short-term exposures, and unlikely to
express the long-term changes that we need in order to
investigate chronic diseases.
Epigenomics
Epigenomics involves the study of epigenetic processes,
which are independent of DNA sequence and are involved
in the inhibition of gene expression (gene silencing), on a
large scale [22-24]. It benefits from the robustness of tech-
nologies for genomics. Altered gene silencing plays a
causal role in human diseases [25-28]. Epigenetic modifi-
cations may provide a plausible link between environ-
mental exposures and alterations in gene expression that
might lead to disease phenotypes. A large amount of lab-
oratory animal studies already provide evidence that sup-
ports the role of environmental epigenetics in disease
Table 1: "-omics" in Environmental Health (except genomics).
Transcriptomics Epigenomics Proteomics Metabolomics
Definition & 
sources of 
samples
Focuses on gene expression 
profiling, which is the 
assessment of the mixture of 
mRNAs that is present in a 
specific biological sample. 
mRNA from all types of 
tissues can be used.
Focuses on epigenetic changes 
in DNA and chromatin and on 
their impact on regulation of 
gene expression. These 
changes are independent of 
DNA sequence, and are 
involved in 'gene silencing'. 
Genomic DNA from all types 
of tissues can be used.
The study of proteins carried 
out to understand the amount 
and functioning of proteins in 
biological systems. All types of 
tissues and biofluids can be 
used for proteomic analysis. 
Plasma, a readily accessible 
fluid is most commonly used.
The measurement of all the 
metabolites in a specified 
biological sample. Samples of a 
biological origin are analyzed 
using techniques that produce 
simultaneous detection, 
thereby providing metabolite 
profiles. It is mainly conducted 
on bio-fluids such as urine or 
plasma, and sometimes tissue 
extracts, in vitro cultures, and 
supernatants.
Tools
used
A quantitative technique is 
used to associate differences 
in mRNA mixtures originating 
from different groups of 
individuals to phenotype 
differences between the 
groups. It is strongly 
constrained by the intrinsic 
heterogeneity and instability 
of mRNA. Both the presence 
of specific forms of mRNA 
and the levels in which these 
forms occur are parameters 
that provide information 
concerning gene expression. 
Microarray is the most 
commonly used research tool.
Currently limited to the 
analysis of gene methylation 
profiles. The standard method 
consists in sequencing of 
DNA segments containing 
potentially methylated 
fragments after modification 
of DNA with sodium bisulfite, 
which selectively modifies 
non-methylated cystosine, 
thus creating a base change 
which does not take place 
when cytosine is methylated. 
This change can be identified 
either by sequencing or by 
genotyping using custom-
made 'genome-wide' 
oligonucleotide arrays.
Reasonable consensus on the 
use of mass spectrometry for 
final identification of proteins/
peptides but technologies for 
sample fractionation are 
variable. These technologies 
rely on 3 main approaches: (1) 
2 dimensional electrophoresis 
to select protein spots that 
are eluted from gels and 
analysed by MS; (2) combined 
chromatographic approaches 
to trap abundant proteins and 
separate the less abundant 
ones before MS; (3) use of 
matrixes of immobilized 
chemicals to adsorb proteins 
based on different criteria 
(charge, hydrophobicity, 
affinity, binding to specific 
ions), followed by desorption 
and MS (SELDI/TOF).
A variety of analytical 
metabolic profiling tools used 
include H NMR spectroscopy 
and MS with a prior online 
separation step like high-
performance liquid 
chromatography, ultra-
performance liquid 
chromatography, or gas 
chromatography.
Analysis Hierarchical clustering and 
principal component analysis 
are commonly used statistical 
approaches for the 
identification of gene sets. For 
the interpretation of the 
relevance of differently 
expressed gene sets, data 
analysis approaches that are 
able to integrate microarray 
data with prior knowledge on 
the involvement of genes in 
biological processes are 
needed.
Conventional statistical 
methods are used to detect 
disease - gene methylation 
associations. Analyses of 
genome-wide methylation 
data involve hierarchical 
clustering and discriminant 
analysis.
Current approaches to 
analyze the protein 
composition of biofluids or 
tissue homogenates generate 
large amounts of data. A 
variety of statistical methods 
are currently available to 
epidemiologists including 
discriminant analysis. Both 
random (measurement) and 
systematic (bias) errors 
should be considered as a 
necessary component of 
proteomic analyses.
Data generated by these 
analytical techniques are often 
combined with multivariate 
data analysis, e.g. (orthogonal) 
partial least square, clustering, 
discriminant analyses and 
other similar approaches for 
generating and interpreting 
the metabolic profiles of the 
investigated samples.Environmental Health 2009, 8:54 http://www.ehjournal.net/content/8/1/54
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susceptibility [25]. Epigenomics is mainly based on a few
comprehensively studied mechanisms: (a) DNA methyla-
tion, which takes place at the carbon-5 position of cyto-
sine in CpG dinucleotides, (b) changes to the chromatin
packaging of DNA by post-translational 'histone modifi-
cation', and more recently (c) changes in RNA interference
by non-coding RNAs such as microRNA and siRNA.
In mice, maternal dietary methyl-donor supplementation
with folic acid, vitamin B, choline and betaine was shown
to result in an increase in DNA methylation at CpG sites,
thus demonstrating that the effect of a mother's diet dur-
ing pregnancy on the adult phenotype of her offspring
was directly linked to DNA-methylation changes in the
epigenome [25]. A few more studies on maternal dietary
exposure, e.g. to phytoestrogen genistein during gestation
given at a level comparable to that of human consump-
tion with high soy diets, are particularly interesting as
these results suggest the possibility that hypermethylating
dietary supplements could reduce the effects of environ-
mental toxicants, which tend to cause DNA hypomethyl-
ation [25].
Recent experiments have shown that epigenetic changes
are associated with chromatin remodelling and regulation
of gene expression that underlie the development of the
metabolic syndrome, and to other common diseases like
atherosclerosis and type 2 diabetes [29]. Deciphering epi-
genetic processes should allow us to target the develop-
ment of new diets and drugs to prevent aberrant gene
silencing, which may be involved in resistance to treat-
ment. The importance of DNA methylation in cancer has
also been established, and research now includes the
mechanisms by which other chromatin modifications
play a role in cancer development [30]. In particular, the
link between covalent histone modifications and nucleo-
somal remodeling is increasingly being explored [30,31].
Also several environmental exposures have been associ-
ated with altered levels of gene methylation. In one study,
decreased repeated-element methylation in gene LINE-1
was observed after exposure to traffic particles (beta = -
0.09; 95% CI, -0.17 to -0.01; P = 0.03) [32]. Also airborne
benzene was associated with a significant reduction in
LINE-1 (-2.33% for a 10-fold increase in airborne benzene
levels; P = 0.009) and AluI (-1.00%; P = 0.027) methyla-
tion. Hypermethylation in p15 (+0.35%; P = 0.018) and
hypomethylation in MAGE-1 (-0.49%; P = 0.049) were
associated with increasing airborne benzene levels [33] In
another study, Rusiecki et al found inverse correlations
between global methylation levels and POP (Persistent
Organic Pollutant) concentrations in the blood of Inuit
populations [34]. Linear regressions, adjusting for age and
cigarette smoking, showed statistically significant inverse
linear relationships mainly for the Alu assay for p, p'-DDT
(1,1,1-trichloro-2,2-bis(p-chlorophenyl)ethane; beta = -
0.26), p, p'-DDE [1,1-dichloro-2,2-bis(p-chlorophenyl)
ethylene; beta = -0.38], beta-hexachlorocyclohexane (beta
= -0.48), oxychlordane (beta = -0.32), alpha-chlordane
(beta = -0.75), mirex (beta = -0.27), sum of polychlorin-
ated biphenyls (beta = -0.56), and sum of all POPs (beta
= -0.48). Linear regressions for the LINE-1 assay showed
beta estimates of similar magnitudes to those using the
Alu assay, however, none was statistically significant.
Proteomics
The proteome consists of all proteins present in specific
cell types or tissues and, in contrast to the genome, it is
highly dynamic over time, between cell types and in
response to the environment. Proteomics is perhaps the
least mature of the "-omic" technologies. Whether agent-
specific changes can be identified is a key question to be
answered about proteomic approaches (note, the same
issue applies to other "-omics", such as metabolomics)
and the issue will be resolved only after a much larger
body of proteomic data on exposed cells, tissues, and
biofluids is collected and analyzed [35]. Proteomic
approaches are twofold: the first is the standardisation of
high-throughput methods, and the second is to combine
extensive protein fractionation, removal of abundant pro-
teins and tandem MS/MS analysis of peptide sequence
data to allow protein identification.
Joo et al performed proteomic analysis of plasma proteins
among workers exposed to benzene and matched unex-
posed controls, and associated up-regulation of specific
proteins with lymphocyte DNA damage [36]. Using MS
and Western blot, they found statistically significant dif-
ferences in protein profiles between the exposed and
unexposed subjects. The specific proteins that were found
to be up-regulated in benzene exposed workers were TCR
beta, FKBP51 and MMP13. Vermeulen et al examined the
impact of benzene on the human serum proteome in a
study of benzene- exposed workers and unexposed con-
trols, where protein-expression patterns were analysed by
SELDI-TOF MS. They found that three proteins were con-
sistently down-regulated in the exposed group compared
to controls and all proteins were highly inversely corre-
lated with individual estimates of benzene exposure (r >
0.75) [37].
Proteomics has been useful in the field of cancer, particu-
larly in the potential discovery of new biomarkers that
may improve the diagnosis of prostate and other cancers
[38]. Proteomic approaches may also provide insights
into the disease mechanism of rheumatic disease [39,40].
Lopez-Pedrera reviews how recent genomic and pro-
teomic approaches have provided new insights into
autoimmune diseases [41]. Obesity, which is caused by a
combination of genetic predisposition and environmen-Environmental Health 2009, 8:54 http://www.ehjournal.net/content/8/1/54
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tal factors, is an area where proteomic approaches are also
being applied. Barcelo-Batllori and Gomis discuss the
application of proteomics in understanding the pathogen-
esis or the molecular mechanism of obesity [42].
However proteomics is still open to several methodologi-
cal problems that have not been solved yet. The most con-
troversial example has been in reporting a distinctive
pattern of low-molecular weight proteins that character-
ises the sera of women with early-stage ovarian cancer that
is very rarely found in control sera [43]. The study was
later refuted by others who offered alternative interpreta-
tions of the initial observations [44]. This was a case
where the basic epidemiologic principle of treating sam-
ples from cases identically to those from controls was pos-
sibly not followed, with the apparent differences between
cases and controls reflecting artefacts of sample handling
[45].
Metabolomics
Changes in gene and protein expression can alter metabo-
lism in particular ways that can provide distinct signa-
tures. The metabolome is the biochemical network
consisting of small molecules (e.g. lipids, vitamins) also
known as metabolites. Metabolites are involved in energy
transmission in cells by interacting with other biological
molecules following metabolic pathways. The metabo-
lome is highly variable and time dependent and consists
of a wide range of different chemical structures. The most
important challenge in this field is to acquire qualitative
and quantitative information on metabolites that occur
under normal circumstances in order to be able to detect
perturbations in the complement of metabolites due to
changes in environmental factors. Global metabolomic
profiling may be more amenable than transcriptomic or
proteomic profiling to high-throughput screening, as sug-
gested for example by studies showing that the main yeast
metabolome consists of fewer than 600 low-molecular-
weight compounds. It should be noted however that the
yeast has only 4,000 genes and is a unicellular organism,
representing thus an oversimplified model to study
humans. Substantial metabolomic analysis of exposure
and effects will be needed to address the possibilities
offered by this approach [35,46]. Global metabolomic
analysis in exposure studies in laboratory animals has just
begun, but the low-level exposures of interest in large
populations have not yet been addressed.
Metabolomic studies are performed with noninvasive
samples such as biofluids and breath condensate as well
as on tissues in vivo. Profiles within a tissue or cell are
compared with profiles in biologic fluids or with cell
secretion products to understand the metabolic conse-
quences of xenobiotic-induced toxicity. Examples of this
approach are the studies by Waters and colleagues, where
NMR and pattern recognition analysis were used to inves-
tigate time-related metabolic effects of α-naphthylisothio-
cyanate on liver, urine, and plasma in laboratory animals
[47,48]. Waters and colleagues found an association
between hepatic lipidosis and increased urinary excretion
of taurine and creatine. In addition, there was reduced uri-
nary excretion of intermediates in the tricarboxylic acid
cycle and increased excretion of plasma ketone bodies.
These studies enabled a clearer understanding of key met-
abolic effects during the development of and recovery
from toxic lesions. In the past, there was a failure in spe-
cificity for cancer, which hampered biomarker discovery
by metabolomics, but technologies like NMR and MS are
being reapplied to study a range of cancers [49,50].
Recently a metabolomic study has been successfully
applied to epithelial ovarian cancer and was apparently
able to discriminate women with epithelial ovarian cancer
from healthy controls, based on 1H NMR spectroscopic
profiles of preoperative serum specimens [49].
Holmes et al [51] used a large-scale exploratory analytical
approach to investigate metabolic phenotype variation
across and within four human populations, based on 1H
NMR spectroscopy. Metabolites discriminating across
populations were then linked to data for individuals on
blood pressure. They analysed spectra from two 24-hour
urine specimens for each of 4,630 participants from the
INTERMAP epidemiological study, involving 17 popula-
tion samples in China, Japan, UK and USA. They showed
that urinary metabolite excretion patterns for East Asian
and western population samples, with contrasting diets,
diet-related major risk factors, and coronary heart disease/
stroke rates, were significantly differentiated (P < 10(-
16)), as were Chinese/Japanese metabolic phenotypes,
and subgroups with differences in dietary vegetable/ani-
mal protein and blood pressure. Among discriminatory
metabolites, they quantified four and showed associa-
tions (P < 0.05 to P < 0.0001) of mean 24-hour urinary
formate excretion with blood pressure in multiple regres-
sion analyses. Mean 24-hour urinary excretion of alanine
(direct) and hippurate (inverse), reflecting diet and gut
microbial activities, were also associated with blood pres-
sure [51].
Discussion
The prevailing model of "environmental disease" for dec-
ades has been influenced by toxicology, with single agents
evaluated at a time, and dose as a key issue. A more recent
model, which was not overall very successful, was that of
"gene-environment" interactions in which environmental
agents at low doses interact with individual genetic sus-
ceptibility. What has not been explored extensively yet is
another potential model for the effects of low doses and
the absence of thresholds, represented by acquired suscep-
tibility and the cumulative effects of different exposures.Environmental Health 2009, 8:54 http://www.ehjournal.net/content/8/1/54
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The concept of "clinical vulnerability" could explain why
small changes in exposure can have big effects, if they
occur in a population of vulnerable subjects. The concept
of acquired "clinical vulnerability" is related to previous
insults/pathophysiological changes that predispose to dis-
ease.
The new "-omics" can be extremely useful in tracing the
"history" of such insults and to reflect the cumulative
effect of different exposures. However, the success of "-
omics" applications to epidemiology will depend on a
coherent and effective model of disease, that addresses
issues such the role of environmental low-level exposures.
The ultimate goal of using "-omics" technologies to iden-
tify environmental causes of disease is to derive an inte-
grated view of the biological processes involved in the
continuum from exposure to disease. Although high-sen-
sitivity and data-rich toxicogenomic approaches may
already be feasible for analyzing human responses to
environmental stressors in some settings, applying these
technologies to human populations exposed to low-level
environmental contaminants will require considerably
more development. In this context, the integration of
information from multiple toxicogenomic approaches
may provide significantly more analytical power than any
one approach alone.
Current limitations of "-omics" include low reproducibil-
ity across laboratories, high intra-individual variability
that hampers inter-individual comparisons, high costs,
difficulties in data analysis and uncertainties in biological
interpretation (see table 2). Type I, II, and III errors need
to be addressed. Type I error refers to false positive results
deriving from the large number of comparisons. This can
be tackled with in-built replication with repeat measures
in independent studies. Type II error derives from the rel-
ative lack of sensitivity of some techniques and the ensu-
ing false negatives issue. Type III error refers to the lack of
relevance of some biomarkers, with uncertain biological
meaning, for the interpretation of exposure disease rela-
tionships. Lumbreras et al discuss some of the sources of
errors in regard to "-omics" based diagnostic techniques
and their solutions, and the effects on diagnostic accuracy
[52,53].
There is also a challenge for accurate exposure assessment
of environmental exposures with "-omics." Wild, for
example, has expressed "the need for developing methods
with the same precision for an individual's exposure, as
we have for the individual's genome" [54]. He goes on to
describe the concept of an 'exposome' which encompasses
lifetime environmental exposure starting from prenatal
period, and stresses the importance of even partial, tar-
geted understanding of exposure, in addition to the
genome, that could provide valuable advances. A prospec-
tive cohort study design can be carried out to best address
the exposure biomarker approach, because it gives oppor-
tunities for repeat measures, as well as collection of sam-
ples before the onset of disease.
"-Omics" has the potential to play an important role in
the generation of new insights into the etiology of disease
and gene-environment interactions, but it is important to
learn "what technologies can be usefully applied to which
questions." [45] With the development of validated tech-
Table 2: Using "-omics": advantages and limitations
Advantages Use in large, hypothesis-free investigations of the whole complement of relevant biological molecules.
Better understanding of phenotype-genotype relations.
May provide insights into the impact of interactions between environmental conditions and genotypes, and mechanistic insights into 
disease aetiology.
Limitations Limitations arising from cost of assays, quality of biological material available (e.g. instability of RNAs), and the amount of labour 
needed.
Techniques still in their discovery state and new leads need to be carefully investigated and compared to existing biological 
information from in vivo and in vitro tests.
New leads in the discovery of novel intermediate markers need to be confirmed in other independent studies preferably using 
different platforms.
It is important to bear in mind that moving from promising techniques to successful application of biomarkers in occupational and 
environmental medicine requires not only the standardization and validation of techniques, but also appropriate study designs and 
sophisticated statistical analyses for interpretation of study results (i.e. issue of multiple comparisons and false positives).Environmental Health 2009, 8:54 http://www.ehjournal.net/content/8/1/54
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nologies, appropriate study designs, adequate sample
size, inclusion of quality control and advanced statistical
methods for data interpretation, "-omics" could poten-
tially contribute significantly to the identification of envi-
ronmental causes of disease and will help the field
progress towards an integrated view of the interaction
between environment and human health.
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